129 related articles for article (PubMed ID: 38271397)
1. Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.
Xiong W; Xu T; Liu X; Zhang L; Yuan Y
Cancer; 2024 Apr; 130(S8):1488-1498. PubMed ID: 38271397
[TBL] [Abstract][Full Text] [Related]
2. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis.
Lei L; Chen R; Fan L; Zheng W; Wang X
Ann Palliat Med; 2022 Jul; 11(7):2382-2394. PubMed ID: 35927773
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer.
Lu H; Zha S; Zhang W; Wang Q; Jiang D; Xu X; Zheng X; Qiu M; Shan C
BMC Cancer; 2021 Jul; 21(1):830. PubMed ID: 34275458
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer.
Sun S; Tang L; Zhang J; Lv F; Wang Z; Wang L; Zhang Q; Zheng C; Qiu L; Jia Z; Lu Y; Liu G; Shao Z; Wang B; Hu X
Int J Nanomedicine; 2014; 9():1443-52. PubMed ID: 24672237
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial.
Sridhar SS; Blais N; Tran B; Reaume MN; North SA; Stockler MR; Chi KN; Fleshner NE; Liu G; Robinson JW; Mukherjee SD; Rahim Y; Winquist E; Booth CM; Nguyen NT; Beardsley EK; Alimohamed NS; McDonald GT; Ding K; Parulekar WR
JAMA Oncol; 2020 Nov; 6(11):1751-1758. PubMed ID: 32940628
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis.
Lee H; Park S; Kang JE; Lee HM; Kim SA; Rhie SJ
Sci Rep; 2020 Jan; 10(1):530. PubMed ID: 31953463
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Study of Efficacy and Safety of Albumin-Bound Paclitaxel in Metastatic Breast Cancer.
Singh RK; Pankaj S; Kumar S; Rajkota V
World J Oncol; 2014 Dec; 5(5-6):204-209. PubMed ID: 29147404
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the clinical benefits of nanoparticle albumin-bound paclitaxel in women with metastatic breast cancer in British Columbia.
Lohmann AE; Speers CH; Chia SK
Curr Oncol; 2013 Apr; 20(2):97-103. PubMed ID: 23559872
[TBL] [Abstract][Full Text] [Related]
12. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
[TBL] [Abstract][Full Text] [Related]
13. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2016 Apr; 16(2):73-81. PubMed ID: 26603443
[TBL] [Abstract][Full Text] [Related]
14. Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
Zhao Y; Lv F; Chen S; Wang Z; Zhang J; Zhang S; Cao J; Wang L; Cao E; Wang B; Hu X
BMC Cancer; 2018 Oct; 18(1):1019. PubMed ID: 30348118
[TBL] [Abstract][Full Text] [Related]
15. Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
Xie Y; Gong C; Zhang J; Wang L; Cao J; Tao Z; Li T; Zhao Y; Li Y; Hu S; Wang B; Hu X
BMC Cancer; 2021 Nov; 21(1):1174. PubMed ID: 34727875
[TBL] [Abstract][Full Text] [Related]
16. Comparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis.
Force RW; Pugmire BA; Culbertson VL
Am Health Drug Benefits; 2010 Jul; 3(4):276-84. PubMed ID: 25126321
[TBL] [Abstract][Full Text] [Related]
17. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
Liu M; Liu S; Yang L; Wang S
BMC Cancer; 2021 Feb; 21(1):118. PubMed ID: 33541289
[TBL] [Abstract][Full Text] [Related]
18. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.
O'Shaughnessy J; Gradishar WJ; Bhar P; Iglesias J
Breast Cancer Res Treat; 2013 Apr; 138(3):829-37. PubMed ID: 23563958
[TBL] [Abstract][Full Text] [Related]
19. Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?
Palumbo R; Sottotetti F; Bernardo A
Ther Adv Med Oncol; 2016 May; 8(3):209-29. PubMed ID: 27239239
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Tamura K; Inoue K; Masuda N; Takao S; Kashiwaba M; Tokuda Y; Iwata H; Yamamoto N; Aogi K; Saeki T; Nakayama T; Sato N; Toyama T; Ishida T; Arioka H; Saito M; Ohno S; Yamauchi H; Yamada K; Watanabe J; Ishiguro H; Fujiwara Y
Cancer Sci; 2017 May; 108(5):987-994. PubMed ID: 28256066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
